Xaftrid 24,0 mg SOLUTION FOR INJECTION
PDF Leaflet Revision Date: 22 March 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Enhances mobilisation of hematopoietic stem cells for autologous transplantation in lymphoma and multiple myeloma.
Dosage (summary)
0.24 mg/kg by subcutaneous injection, administered 6 to 11 hours prior to apheresis after 4 days of G-CSF.
Onset of Action / Duration
Onset: 6-9 hours, Duration: Not specified
Special Populations
- Renal impairment
- Elderly
Pregnancy & Breastfeeding
Contraindicated in pregnancy; unknown if excreted in breast milk.
Key Drug Interactions
- G-CSF
- Rituximab
Contraindications
- Hypersensitivity to plerixafor
- Pregnancy
Common side effects
- Dizziness
- Nausea
- Diarrhoea
- Fatigue
- Injection site reactions
Counselling Points
- Use effective contraception during treatment
- Avoid breastfeeding during treatment
- Report any signs of allergic reactions
Serious warnings
- Potential for leukocyte mobilization in leukemia patients
- Monitor white blood cell and platelet counts
Important Disclaimer
The Xaftrid 24,0 mg SOLUTION FOR INJECTION professional information leaflet below is the property of Aurogen Sa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
